<DOC>
	<DOCNO>NCT01535989</DOCNO>
	<brief_summary>This open label phase I study Inotuzumab Ozogamicin , antibody-targeted intravenous chemotherapy agent compose CD22-targeted antibody link calicheamicin , combination mammalian target rapamycin ( mTOR ) inhibitor Temsirolimus , patient relapsed/refractory CD22+ B-cell non Hodgkin 's lymphoma ( NHLs ) . Both Inotuzumab Ozogamicin Temsirolimus evaluate single agent well combination rituximab patient NHLs . This first study combine two agent together . In present study Inotuzumab Ozogamicin administer intravenously d1 start dose 0.8 /m2 . Temsirolimus administer intravenously day 1,8,15 22 start dose 15mg . Cycles repeat every 28 day .</brief_summary>
	<brief_title>Study Inotuzumab Ozogamicin + Temsirolimus Patients With Relapsed Refractory CD22+ B-cell NHLymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Key inclusion criterion Histologically and/or cytologically confirm relapsed refractory CD22+ Bcell Non Hodgkin 's Lymphomas No limitation prior treatment . Patients must progress least one prior therapy . Adult patient ( age &gt; 18yrs old ) . ECOG status â‰¤ 1 . Life expectancy great 3 month . Adequate organ marrow function . Key exclusion criterion Uncontrolled intercurrent illness Chronic obstructive chronic restrictive pulmonary disease Hepatitis B , C HIV Patients know known central nervous system lymphoma involvement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>B-cell Non Hodgkin 's Lymphomas</keyword>
	<keyword>CD22 positive</keyword>
</DOC>